RheeGen®, a biotechnology company at the forefront of regenerative biology, is expanding its scientific leadership with the addition of a deeply respected molecular biologist. Dr. Zenas George, Ph.D., has joined the company as Science Advisor, bringing with him a remarkable record of innovation across stem cell research, cellular engineering, and molecular therapeutics. His arrival marks an exciting new chapter in RheeGen’s pursuit to redefine what’s possible in regenerative medicine.
For RheeGen’s founder, Dr. Tommy Rhee, the company has always been about pushing boundaries. His vision centers on using the body’s own healing potential as the foundation for a new generation of therapeutics—therapies that don’t just treat symptoms, but activate cellular and molecular systems capable of repairing damage at its source. With expertise rooted in regenerative biology, Dr. Rhee established RheeGen® as a place where cellular engineering, molecular therapeutics, and advanced bioactive systems are brought together under one mission: unlocking complex regenerative pathways to address the most challenging medical needs.
It is a mission that resonates deeply with Dr. George, whose career spans critical contributions to regenerative pathway discovery and stem cell innovation. Known in scientific circles for his work with induced pluripotent stem cells (iPSCs)—a technology that allows adult cells to be reprogrammed into a versatile, embryonic-like state—Dr. George has devoted his career to uncovering how cells communicate, adapt, and regenerate. His expertise in cellular signaling and molecular design brings an essential dimension to RheeGen’s expanding research programs.
Dr. George’s path to becoming one of the field’s emerging leaders began with a curiosity for how life organizes itself at the molecular level. After earning his Ph.D. in Biochemistry from the University of Sussex in the United Kingdom, he immersed himself in research that explored the very building blocks of regenerative function. Over the years, he has contributed to numerous peer-reviewed publications that examine how cells respond to their environment, how tissue regeneration can be accelerated, and how molecular tools can be used to guide and correct biological systems.
His professional journey includes significant roles at highly innovative biotechnology companies. While leading R&D programs at Cellular Engineering Technologies, Dr. George played a central role in advancing iPSC technology and developing new cellular models that better mimic human biological systems. These advances helped pave the way for more precise and scalable regenerative research. Later, as Senior R&D Scientist at Jumpcode Genomics, he helped develop CRISPR-based platforms designed to improve next-generation sequencing—tools that support deeper, more accurate exploration of genetic and molecular pathways.
It is this unique combination of regenerative biology expertise, molecular innovation, and hands-on experience with translational technologies that makes Dr. George such a valuable addition to RheeGen’s advisory team. His insight will help shape the company’s scientific direction, particularly as it integrates bioactive system design with emerging cellular therapies.
For RheeGen®, the timing of Dr. George’s appointment aligns with a period of rapid scientific growth. The company is aggressively investing in platforms that reimagine how cells repair themselves and how regenerative signals can be guided or amplified. Whether developing next-generation bioactive molecules or exploring new mechanisms of cellular communication, RheeGen® is building a research ecosystem that merges advanced science with a strong translational focus.
Dr. George will play a key role in steering these efforts. His deep understanding of regenerative signaling networks and his experience in designing molecular tools provide an invaluable foundation for the company’s next stages of development. He is expected to contribute across multiple active research initiatives, offering strategic guidance on experimental direction, technology integration, and scientific validation.
While RheeGen® has already established itself as an ambitious and forward-thinking presence in the biotech landscape, the addition of Dr. George underscores the company’s commitment to world-class science. His appointment reflects not only the growth of the advisory team but also RheeGen’s broader goal of cultivating partnerships with leading thinkers whose expertise advances both the science and its real-world applications.
RheeGen® is guided by a belief that the next breakthroughs in medicine will come from understanding the body’s regenerative blueprint—how cells communicate, how tissues repair themselves, and how molecular signals orchestrate healing. Dr. George’s work aligns seamlessly with this philosophy. He brings a strong appreciation for both the complexity of regenerative processes and the need for technologies that can translate this complexity into practical, next-generation therapies.
As RheeGen® continues to grow, the company is eager to harness Dr. George’s perspective, curiosity, and scientific rigor. His influence is expected to help shape the development of new regenerative platforms and accelerate the company’s progress toward therapies that can truly transform patient care.
RheeGen’s future is one defined by bold science, collaboration, and a relentless commitment to unlocking the body’s inherent healing capabilities. With the addition of Dr. Zenas George to its advisory team, that future feels more promising than ever.
Learn more at RheeGen.com.
